4Bischoff E. Potency, selectivity, and consequences of nonselectivi- ty of PDE inhibition[J]. Int J Impot Res, 2004,16 Suppl 1:11 - 14.
5Ghanem AG. A case of recurrent transient monocular visual loss af- ter receiving sildenafil [ J ]. Case Rep Ophthalmol Med, 2011, 2011:645089.
6E1 - Domyati MM, E1 - Fakahany HM, Morad KE. Nonarteritic is- chaemic optic neuropathy(NAION) after 36 h of intake of sildena- fil citrate : first Egyptian case [ J ]. Andrologia,2009,41 ( 5 ) : 319 - 321.
7Snodga'ass AJ. Sudden sensorineural hearing loss associated with vardenafil [ J]. Pharmacotherapy ,2010,30( 1 ) : 112.
8Turkcu FM. Central serous chorioretinopathy due to tadalafil use [ J]. Int Ophthalmol,2012.
9Azzouni F, Abu SK. Are phosphodiesterase type 5 inhibitors associ- ated with vision- threatening adverse events? A critical analysis and review of the literature[ J]. J Sex Med, 2011,8(10) :2894 - 2903.
10Wirostko BM. Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randnmised, double masked, placebo controlled trial and open label extension[ J]. BMJ ,2012,344 : e554.
